Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF
Show Display Options
Rank Status Study
1 Enrolling by invitation Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.
Conditions: Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency;   Carnitine-acylcarnitine Translocase (CACT) Deficiency
Intervention: Drug: UX007
2 Available Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency Disease;   ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of;   Barth Syndrome
Intervention: Drug: triheptanoin
3 Recruiting Fatty Acid Oxidation Defects and Insulin Sensitivity
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Normal Volunteers
Interventions: Drug: Intralipid/Heparin;   Drug: Glycerol/Saline;   Drug: Hyperinsulinemic euglycemic clamp
4 Completed High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Carnitine Palmitoyltransferase 2 Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Intervention: Behavioral: Diet counseling
5 Active, not recruiting An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD);   Carnitine Palmitoyltransferase (CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency
Intervention: Drug: UX007
6 Completed Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
Conditions: Carnitine Palmitoyltransferase II Deficiency;   Very Long Chain Acyl Coa Dehydrogenase Deficiency
Interventions: Drug: Bezafibrate;   Other: Placebo
7 Completed Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase 2 (CPT2) Deficiency;   Mitochondrial Trifunctional Protein (TFP) Deficiency;   Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency
Intervention: Drug: Triheptanoin

Indicates status has not been verified in more than two years